Chief Science Officer and Head of Research and Development
Dr. Eilon Kirson joined Novocure in 2002 and served as Chief Medical Officer until 2012 when he was promoted to Chief Science Officer and Head of Research and Development. Dr. Kirson has global responsibility for Novocure’s preclinical and clinical and product development programs, as well as the company’s regulatory strategy. Throughout his tenure at Novocure, Dr. Kirson has led the development of TTFields therapy from pre-clinical testing to large, multi-center phase III studies and through multiple regulatory approvals. Dr. Kirson previously served as Head of Electrophysiology at Carmel Biosensensors. Dr. Kirson received his B.Med.Sc., M.D. and Ph.D. in Biophysics from the Hebrew University and underwent his residency in neurology at Sheba Medical Center, Tel Ha-Shomer Hospital, Israel.
clinical trialsOur mechanism of action is broadly applicable across a variety of solid tumors.
novocuretrial.comThe science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.